Home / Market News / $ACAD
fiscal.ai Corporate Catalyst Impact 65/100 ● negative

Morgan Stanley Lowers Price Target for ACADIA Pharmaceuticals Inc.

Nov 13, 2026, 7:07 PM UTC · Primary ticker $ACAD

Morgan Stanley has lowered its price target for ACADIA Pharmaceuticals Inc. from $28 to $24. This adjustment signals a revised, less optimistic valuation by a major investment bank, which could exert downward pressure on ACADIA's stock price in the short term.

Morgan Stanley, a prominent investment bank, has reduced its price target for ACADIA Pharmaceuticals Inc. from $28 to $24. This action indicates a revised, less favorable outlook on the company's future performance or valuation by a significant market participant. The immediate impact is likely negative for ACADIA's stock, as a lower price target from a respected firm can influence investor sentiment and potentially lead to selling pressure. For traders, this presents a short-term bearish signal, suggesting potential downside or limited upside in the near future. The long-term implications depend on the underlying reasons for Morgan Stanley's revised assessment, which are not detailed in this filing but could relate to clinical trial outcomes, competitive landscape, or market conditions.

$ACAD negative Price target lowered by major analyst
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.